Related Experiment Video
Updated: May 31, 2026
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host
Peilong Lai1, Jianyu Weng, Zesheng Lu
1Department of Haematology, Guangdong General Hospital, Guangzhou, P.R. China.
Insights
New research identifies CD28 and PI3K as potential biomarkers for chronic graft-versus-host disease (cGVHD). Upregulation of these molecules may predict cGVHD onset and progression after stem cell transplantation.
Area of Science:
- Immunology
- Oncology
- Transplantation Medicine
Background:
- Chronic graft-versus-host disease (cGVHD) is a significant complication following allogeneic hematopoietic stem cell transplantation (HSCT).
- Current diagnostic and prognostic tools for cGVHD lack predictive accuracy.
- There is a critical need for reliable biomarkers to predict cGVHD risk and progression.
Purpose of the Study:
- To identify novel gene expression biomarkers for predicting cGVHD.
- To investigate the differential gene expression profiles in patients with and without cGVHD post-HSCT.
- To validate potential biomarkers for clinical application in cGVHD management.
Main Methods:
- Peripheral blood mononuclear cells were collected from HSCT patients with and without cGVHD.
- Gene expression profiling was performed using Affymetrix GeneChip Human U133 Plus 2.0 microarrays.
- Quantitative real-time polymerase chain reaction and flow cytometry were used for biomarker validation.
Main Results:
- Microarray analysis revealed significant differential expression of 3180 genes between cGVHD and non-GVHD groups.
- CD28 and PI3K were identified as significantly upregulated in patients with cGVHD.
- Validation confirmed the elevated expression of CD28 and PI3K in cGVHD samples.
Conclusions:
- Upregulation of CD28 and PI3K is associated with the onset and progression of cGVHD.
- CD28 and PI3K show promise as potential predictive biomarkers for cGVHD.
- Further research is warranted to explore the therapeutic implications of targeting CD28 and PI3K in cGVHD.
Abstract:
Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Currently, no reliable biomarkers are available to predict the onset or progression of cGVHD. Therefore, in this study, we collected peripheral blood mononuclear cells from four patients with cGVHD and four ones with non-GVHD after hematopoietic stem cell transplantation and employed Affymetrix GeneChip Human U133 Plus 2.0 microarrays to screen the genes differentially expressed in cGVHD versus non-GVHD groups, with the aim to identify potential clinical biomarkers to predict cGVHD risk or progression. Microarray analysis demonstrated that the expression of 3180 genes changed significantly in cGVHD versus non-GVHD, with 879 genes upregulated and 2301 genes downregulated. Among them we chose CD28 and PI3K as candidates for further verification. Flow cytometry and quantitative real-time polymerase chain reaction analysis confirmed the significant upregulation of CD28 and PI3K in samples from patients with cGVHD compared with patients with non-GVHD, respectively. In conclusion, our study suggested that the upregulation of CD28 and PI3K contributed to the onset and progression of cGVHD and provided evidence that CD28 and PI3K may serve as promising biomarkers for cGVHD.
More Related Videos
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
10:29Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
Published on: August 29, 2012